Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Nov;48(11):4438-40.
doi: 10.1128/AAC.48.11.4438-4440.2004.

Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp

Ashfaque Hossain  1 , M J Ferraro, R M Pino, R B Dew 3rd, E S Moland, T J Lockhart, K S Thomson, R V Goering, N D Hanson
Affiliations

Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp

Ashfaque Hossain et al. Antimicrob Agents Chemother. 2004 Nov.

Abstract

A strain of an Enterobacter sp. with reduced susceptibility to imipenem, which produced a plasmid-mediated class A carbapenem-hydrolyzing enzyme, KPC-2 beta-lactamase, was isolated from a patient with sepsis at a Boston hospital. This is the first report of the production of a plasmid-encoded KPC-2 beta-lactamase by an Enterobacter sp.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Plasmid profiles. Lane 1, Escherichia coli transconjugant; lane 2, Enterobacter sp.; lane 3, supercoiled plasmid ladder (Invitrogen).
See this image and copyright information in PMC

References

    1. Hanson, N. D., E. S. Moland, A. Hossain, S. A. Neville, I. B. Gosbell, and K. S. Thomson. 2002. Unusual Salmonella enterica serotype Typhimurium isolate producing CMY-7, SHV-9 and OXA-30 β-lactamases. J. Antimicrob. Chemother. 49:1011-1014. - PubMed
    1. Jones, R. N., D. J. Biedenbach, and A. C. Gales. 2003. Sustained activity and spectrum of selected extended-spectrum β-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int. J. Antimicrob. Agents 21:1-7. - PubMed
    1. Livermore, D. M. 2002. The impact of carbapenemases on antimicrobial development and therapy. Curr. Opin. Investig. Drugs 3:218-224. - PubMed
    1. Miriagou, V., L. S. Tzouvelekis, S. Rossiter, E. Tzelepi, F. J. Angulo, and J. M. Whichard. 2003. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47:1297-1300. - PMC - PubMed
    1. Poirel, L., and P. Nordmann. 2002. Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr. Pharm. Biotechnol. 3:117-127. - PubMed

Publication types

LinkOut - more resources